{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T13:01:43Z","timestamp":1786539703572,"version":"build-2736575974"},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2022,4,16]],"date-time":"2022-04-16T00:00:00Z","timestamp":1650067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>This secondary analysis of the phase 3 ENSEMBLE trial (NCT04505722) assessed the impact of preexisting humoral immunity to adenovirus 26 (Ad26) on the immunogenicity of Ad26.COV2.S-elicited severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)\u2013specific antibody levels in 380 participants in Brazil, South Africa, and the United States. Among those vaccinated in Brazil and South Africa, 31% and 66%, respectively, had prevaccination serum-neutralizing activity against Ad26, with little preexisting immunity detected in the United States. Vaccine recipients in each country had similar postvaccination spike (S) protein\u2013binding antibody levels, indicating that baseline immunity to Ad26 has no clear impact on vaccine-induced immune responses.<\/jats:p>","DOI":"10.1093\/infdis\/jiac142","type":"journal-article","created":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T11:10:33Z","timestamp":1649934633000},"page":"979-982","source":"Crossref","is-referenced-by-count":23,"title":["Impact of Preexisting Anti\u2013Adenovirus 26 Humoral Immunity on Immunogenicity of the Ad26.COV2.S Coronavirus Disease 2019 Vaccine"],"prefix":"10.1093","volume":"226","author":[{"given":"Mathieu","family":"Le Gars","sequence":"first","affiliation":[{"name":"Janssen Vaccines and Prevention , Leiden , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerald","family":"Sadoff","sequence":"additional","affiliation":[{"name":"Janssen Vaccines and Prevention , Leiden , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Struyf","sequence":"additional","affiliation":[{"name":"Janssen Research and Development , Beerse , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Heerwegh","sequence":"additional","affiliation":[{"name":"Janssen Research and Development , Beerse , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Truyers","sequence":"additional","affiliation":[{"name":"Janssen Research and Development , Beerse , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Hendriks","sequence":"additional","affiliation":[{"name":"Janssen Vaccines and Prevention , Leiden , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenda","family":"Gray","sequence":"additional","affiliation":[{"name":"South African Research Council , Cape Town , South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Grinsztejn","sequence":"additional","affiliation":[{"name":"Evandro Chagas National Institute of Infectious Diseases\u2013Fiocruz , Rio de Janeiro , Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A","family":"Goepfert","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Alabama , Birmingham, Alabama , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanneke","family":"Schuitemaker","sequence":"additional","affiliation":[{"name":"Janssen Vaccines and Prevention , Leiden , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Macaya","family":"Douoguih","sequence":"additional","affiliation":[{"name":"Janssen Vaccines and Prevention , Leiden , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,4,16]]},"reference":[{"key":"2022092122005337800_jiac142-B1","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N Engl J Med"},{"key":"2022092122005337800_jiac142-B2","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1016\/j.vaccine.2020.09.018","article-title":"Vaccines based on replication incompetent Ad26 viral vectors: standardized template with key considerations for a risk\/benefit assessment","volume":"39","author":"Custers","year":"2021","journal-title":"Vaccine"},{"key":"2022092122005337800_jiac142-B3","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"396","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"2022092122005337800_jiac142-B4","doi-asserted-by":"crossref","first-page":"e688","DOI":"10.1016\/S2352-3018(20)30229-0","article-title":"Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1\/2a study","volume":"7","author":"Baden","year":"2020","journal-title":"Lancet HIV"},{"key":"2022092122005337800_jiac142-B5","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2034201","article-title":"Interim results of a phase 1-2a trial of Ad26.COV2.S COVID-19 vaccine","volume":"384","author":"Sadoff","year":"2021","journal-title":"N Engl J Med"},{"key":"2022092122005337800_jiac142-B6","doi-asserted-by":"crossref","first-page":"e1003813","DOI":"10.1371\/journal.pmed.1003813","article-title":"Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: a randomised, placebo-controlled phase II clinical trial in Africa","volume":"18","author":"Barry","year":"2021","journal-title":"PLoS Med"},{"key":"2022092122005337800_jiac142-B7","doi-asserted-by":"crossref","first-page":"585","DOI":"10.7326\/M20-5306","article-title":"A double-blind, randomized, placebo-controlled phase 1 study of Ad26.ZIKV.001, an Ad26-vectored anti-zika virus vaccine","volume":"174","author":"Salisch","year":"2021","journal-title":"Ann Intern Med"},{"key":"2022092122005337800_jiac142-B8","doi-asserted-by":"crossref","first-page":"e1003865","DOI":"10.1371\/journal.pmed.1003865","article-title":"Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: a randomised, placebo-controlled, multicentre phase II clinical trial","volume":"19","author":"Anywaine","year":"2022","journal-title":"PLoS Med"},{"key":"2022092122005337800_jiac142-B9","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0140-6736(18)31364-3","article-title":"Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1\/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)","volume":"392","author":"Barouch","year":"2018","journal-title":"Lancet"},{"key":"2022092122005337800_jiac142-B10","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1056\/NEJMoa2117608","article-title":"Final analysis of efficacy and safety of single-dose Ad26.COV2.S","volume":"386","author":"Sadoff","year":"2022","journal-title":"N Engl J Med"},{"key":"2022092122005337800_jiac142-B11","doi-asserted-by":"crossref","first-page":"5046","DOI":"10.1128\/JCM.41.11.5046-5052.2003","article-title":"Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors","volume":"41","author":"Sprangers","year":"2003","journal-title":"J Clin Microbiol"},{"key":"2022092122005337800_jiac142-B12","author":"Sadoff"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiac142\/43904381\/jiac142.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/226\/6\/979\/45966879\/jiac142.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/226\/6\/979\/45966879\/jiac142.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T22:05:43Z","timestamp":1663797943000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/226\/6\/979\/6569363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,16]]},"references-count":12,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,4,16]]},"published-print":{"date-parts":[[2022,9,21]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiac142","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,9,15]]},"published":{"date-parts":[[2022,4,16]]}}}